Want to join the conversation?
$ABBV 2Q15 Call: The acquisition of Pharmacyclics will also drive strong financial benefits, further diversifying our revenue base significantly enhancing our revenue growth. We expect accretion related to the acquisition in excess of $0.60 per share in 2019 ramping to more than a dollar per share in 2021.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.